Maven Clinic Spent a Decade Selling Women’s Health to Bosses. Now It’s Coming Back for Everyone

The first version of Maven Clinic had a clean pitch and miserable timing. In 2015, a woman could open an app, choose among practitioners and book a short video visit. One early patient highlighted by Time paid $18 for a ten-minute appointment and had an inhaler in hand roughly two and a half hours later. Today that sounds ordinary. Then it sounded like a dare.

Founder Kate Ryder’s team learned the difference in city parks, where they tried to persuade passersby to meet clinicians through a screen. The strangers did not oblige. Virtual-care coverage was scarce, consumer trust was thinner and COVID-19 had not yet taught half the planet how to point a camera at its own face. Ryder’s later verdict was blunt: direct-to-consumer was the wrong path because Maven was too early.

So Maven kept the patient and changed the payer. Instead of asking a woman to discover, trust and buy a new form of care, it sold maternity support to her employer. That decision sent the company on a ten-year detour through HR departments, health plans, fertility clinics, Medicaid populations and the administrative swamp of American medicine. By 2026 Maven said it served more than 2,300 employers and health plans, supported 28 million covered lives and operated across 175 countries.

“The vision made sense, but we were wrong about one thing. Direct-to-consumer wasn’t the right path. We were too early.”Kate Ryder, founder and CEO

The product is the handoff

Maven is commonly called a telehealth company, which is accurate in the way that calling an airport a runway is accurate. Video appointments matter, but the company’s more interesting work happens between stops. Members can reach providers in more than 30 specialties, receive a personalized care plan, message a dedicated Care Advocate, join classes and communities, navigate insurance and get steered toward local care when a screen will not do.

The programs follow the long, untidy arc of family health: fertility and family building; maternity and newborn care; parenting and pediatrics; menopause and midlife. The provider roster includes OB-GYNs and pediatricians, but also doulas, lactation consultants, pelvic-floor therapists, reproductive endocrinologists, mental-health providers, nutritionists, adoption coaches and surrogacy coaches. It is less a digital doctor’s office than an air-traffic controller for specialists that traditional coverage often leaves in separate terminals.

For employers, Maven also manages money. Maven Wallet tracks eligible reimbursements for services such as fertility treatment, adoption, surrogacy, doula care, travel or childcare, depending on the benefit an organization buys. Maven Managed Benefit goes further: it combines fertility coverage, a clinic network, pharmacy support, conception coaching and financial administration. An employer can offer cycle-based coverage or a lifetime maximum inside the same app where a member receives care.

The boss paid for the clinic

The enterprise model solved two problems at once. Employees gained access without making a fresh purchasing decision during a pregnancy or fertility crisis. Maven gained a buyer with a reason to care about expensive outcomes: fewer unnecessary emergency visits, lower rates of C-sections and neonatal intensive care, and more parents returning to work.

Those are Maven’s reported outcomes, drawn from its claims studies and member data; they are not a promise for every population. The underlying commercial logic is still clear. A maternity app is easy for a benefits director to cut. A program that can connect engagement to lower hospital costs is much harder to dismiss. Maven has built its sales argument around that difference, and says its care model is now backed by more than 40 peer-reviewed studies.

Scale followed. Maven raised $45 million in 2020, $110 million in 2021 and became the first U.S. unicorn devoted to women’s and family health. A $90 million round arrived in 2022. In October 2024, StepStone Group led a $125 million Series F at a reported $1.7 billion valuation, bringing disclosed funding above $425 million. Amazon, Microsoft, AT&T, Morgan Stanley and L’Oréal have all been publicly named as customers.

Fertility care with a different meter running

Maven’s sharpest competitive idea may be hiding in its fertility product. Traditional fee-for-service care pays when procedures happen; an IVF cycle is both treatment and revenue. Maven says its managed benefit is designed around the quickest, safest and most affordable route to a healthy baby. Members begin with education and Trying-to-Conceive Coaching. Those who need treatment can move into a managed clinic and pharmacy network; those who do not avoid spending their benefit on an unnecessary procedure.

Ryder has described charging employers a fixed fee that lets Maven consider medical history, finances and patient preference without being paid for recommending more IVF. In 2024 the company said 30 percent of members struggling to conceive achieved pregnancy without assisted reproductive technology. It also reports a 98 percent singleton pregnancy rate among IVF pregnancies in its managed program, a metric that matters because multiple pregnancies increase clinical risk and cost.

That positioning puts Maven beside Progyny, Carrot Fertility, Kindbody and WIN, while its broader clinic competes with menopause platforms, general telehealth vendors and the health plan’s own maternity line. Maven’s answer is breadth plus integration: fertility support that continues into pregnancy, maternity care that notices mental health, menopause care that accounts for sleep and metabolism, and one benefits layer beneath them.

Then the boomerang came back

In March 2026 Maven reopened direct access to consumers. The company had not changed its mind about the difficulty of selling healthcare one person at a time. The market changed its mind about virtual care. Patients had spent years using telemedicine, wearables, online pharmacies and AI health tools. Meanwhile, Maven’s employer and health-plan customers were asking for care that reached beyond reproductive episodes into hormones, metabolism and midlife.

The first consumer offers make the new economics visible. Hormone Care Essentials costs $150 once. It includes two 20-minute video consultations, up to 20 secure messages, a personalized plan and prescription support; medication and extra visits cost more. GLP-1 Care advertises a $39 first month followed by $150 a month. Medication is separate, with self-pay brand-name options starting at $149 monthly and lower prices possible with insurance.

Maven says it prescribes only FDA-approved GLP-1 medicines, not compounded versions, and pairs prescribing with nutrition, strength support, dose adjustment and side-effect management. The pitch is pointed: women’s hormones, reproductive history, PCOS, postpartum state and menopause should not be footnotes in a generic weight-loss protocol. Whether consumers will pay enough, stay long enough and trust Maven outside an employer portal is the company’s second attempt at the original question.

The boring work became the moat

The enterprise detour changed Maven in ways a pure consumer company might have avoided. Health plans demanded evidence. Employers demanded implementation. Fertility clinics demanded billing rules. International customers demanded local language, regulation and referral networks. In 2023 Maven bought London-based Naytal to strengthen its UK and European presence. In 2026 it said a managed-benefit client could launch in as little as 45 days, with policies intended to keep members in active fertility treatment from being stranded during a vendor change.

This is also where the limitations sit. A virtual clinic cannot perform an ultrasound, deliver a baby, run an IVF lab or stabilize an emergency. Quality depends on the local provider who receives the handoff. Access varies by employer plan, geography, clinical eligibility and insurance. Self-reported improvements are useful signals, not universal clinical guarantees. And an integrated platform can still become one more layer if health records, pharmacy, benefits and local clinicians do not exchange information cleanly.

Maven is adding AI to that plumbing. Ask Maven handles benefit questions, and the company has described using AI to summarize incoming health history before an appointment. The sensible test is not whether a chatbot can sound reassuring. It is whether it gives the correct coverage answer, preserves context and knows when to hand a member to a human. In healthcare, fluent confidence is a bug when the benefit document says otherwise.

What another founder can steal

The playbook will not travel everywhere. It works when an institutional buyer bears a measurable cost, the product can reach enough eligible people, and outcomes can be demonstrated on a useful timeline. It falters when the employer has no financial stake, employees fear sharing sensitive information, local care cannot absorb referrals or the clinical result takes years to observe. It also requires capital and patience: Maven raised hundreds of millions of dollars while assembling its network, evidence and benefit machinery.

The lesson is not that every consumer health startup should sell to HR. It is that timing can be wrong while the underlying need is right. Maven survived that distinction by treating its first failure as information. The company that once asked strangers in a park to try a digital doctor now has a familiar technology, an institutional distribution engine and a new consumer checkout page. The second attempt begins with far less explaining - and far more to prove.

Keep exploring

Maven website Consumer launch note Newsroom LinkedIn Instagram Founder interview